Title : Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.

Pub. Date : 2020

PMID : 32158297






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Fourteen of the 20 patients with ROS1-gene rearrangement received crizotinib therapy, with an objective response rate of 64.28%. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
2 Conclusion: ROS1-gene rearrangement was present at a relatively higher frequency of 2.8% in north Indian patients with lung adenocarcinoma and was successfully targeted by crizotinib therapy. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens